Clinical trials: Cancer of Prostate
Prostate Cancer
Acute Effects of Exercise on the Cortical Silent Period in Prostate Cancer Patients
In Canadian men, prostate cancer (PCa) is the most prevalent form of cancer and the third leading cause of cancer-related death.
- Trial name
- NCT01715064
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- University of Guelph-Humber
Lung Cancer, Solid Tumor (Not Breast or Prostate Cancers)
Cabozantinib in Advanced Solid Malignancies
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01588821
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Erectile Dysfunction, Prostate Cancer
A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
The purpose of the study is to compare the safety and effectiveness of Prograf in the prevention of erectile dysfunction in men after a radical prostatectomy.
- Trial name
- NCT00106392
- Testing
- Tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 131 people
- Sponsor
- Astellas Pharma Inc
Prostatic Neoplasm
Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors
Development and evaluation of an online intervention addressing sexual functioning in gay and bisexual men (GBM) after prostate cancer treatment.
- Trial name
- NCT03343093
- Testing
- Restore Rehabilitation Program, Control
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- University of Minnesota
Prostate Cancer
Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer
The purpose of this study is to evaluate the effect of an initial hormonal treatment gonadotrophin-releasing hormone (GnRH Agonist) on 2 biomarkers (PCA3 and TMPRSS2-ERG), in patients with histologically confirmed and advanced…
- Trial name
- Triptocare (NCT01020448)
- Testing
- Triptorelin (Decapeptyl®)
- Where
- 59 sites in Belgium, Denmark and 8 more
- Volunteers
- 339 people
- Sponsor
- Ipsen
Prostate Cancer
Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
The goal of this clinical research study is to learn more about how the study drug alpharadin (Radium-223) works in patients who have CPRC that has spread to the bone.
- Trial name
- NCT02135484
- Testing
- Alpharadin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
mCRPC
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
- Trial name
- TALAPRO-2 (NCT03395197)
- Testing
- Talazoparib with enzalutamide
- Where
- 370 sites in United States, Argentina and 24 more
- Volunteers
- 1,054 people
- Sponsor
- Pfizer
Small Cell Neuroendocrine Carcinoma, Prostate Cancer
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Despite the low androgen receptor (AR) transcriptional activity of treatment-emergent small cell neuroendocrine prostate cancer, there is persistent AR expression observed in the majority of treatment-emergent small-cell…
- Conditions
- Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma
- Trial name
- NCT04926181
- Testing
- Apalutamide, Cetrelimab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rahul Aggarwal
Metastatic Castration-Resistant Prostate Cancer
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of the phase 2 study is to determine whether Onvansertib is safe and tolerable in adult participants with Metastatic Castration-Resistant Prostate Cancer who have disease progression while receiving abiraterone…
- Trial name
- NCT03414034
- Testing
- Onvansertib, Abiraterone, Prednisone
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Cardiff Oncology
Prostate Cancer
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
The addition of abiraterone acetate to standard treatment of radiotherapy and short-term androgen deprivation will increase the frequency of undetectable PSA.
- Trial name
- NCT01717053
- Testing
- Abiraterone acetate, Androgen deprivation, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Duke University
Adenocarcinoma of the Prostate
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
The primary hypothesis of this study is that outcomes for patients with biochemically recurrent prostate cancer following radical prostatectomy will be improved by the addition of enzalutamide for 6-months compared to…
- Trial name
- NCT02203695
- Testing
- Enzalutamide, SRT
- Where
- 9 sites in United States
- Volunteers
- 86 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy
RATIONALE: Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. PURPOSE: This phase II trial is studying the side effects and how well ultrasound-guided implant radiation…
- Trial name
- NCT00450411
- Testing
- 125-Iodine, 103-palladium
- Where
- 17 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Radiation Therapy Oncology Group
Esophageal Diseases, Gastrointestinal Diseases
Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
The purpose of this study is to determine whether the early identification and more precise intervention of operating room (OR) patient fluid administration optimization using arterial pressure-based cardiac output (APCO) yields…
- Conditions
- Esophageal Diseases, Gastrointestinal Diseases, Disorder of the Genitourinary System, Gynecologic Diseases
- Trial name
- NCT00526331
- Testing
- Vigileo Monitor, FloTrac Sensor
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Gastrointestinal Cancers, Prostate Cancer
Vitamin D for Chemoprevention
This study will help us know the effects of Vitamin D pills in Blacks. The results of this study may be the first step in creating ways to prevent the risks of colon and prostate cancer.
- Conditions
- Gastrointestinal Cancers, Prostate Cancer, Hypertension
- Trial name
- NCT00585637
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Prostatic Neoplasms
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
- Trial name
- ARANOTE (NCT04736199)
- Testing
- Darolutamide (Nubeqa, BAY1841788), Androgen deprivation therapy (ADT)
- Where
- 131 sites in Australia, Brazil and 13 more
- Volunteers
- 669 people
- Sponsor
- Bayer
Bladder Cancer
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
The purpose of this study is to determine whether Patients with Locally Advanced or Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus…
- Trial name
- NCT01126749
- Testing
- Gemcitabine, E7389, Cisplatin
- Where
- 42 sites in United States, Germany and 4 more
- Volunteers
- 92 people
- Sponsor
- Eisai Inc.
Prostate Cancer, Castration Resistant Prostate Cancer
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
This study was conducted in subjects in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms
- Trial name
- NCT01995058
- Testing
- cabozantinib, abiraterone, prednisone
- Where
- 20 sites in United States
- Volunteers
- 54 people
- Sponsor
- Exelixis
Prostate Adenocarcinoma
Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy
This trial studies how well increasing the dose of survivorship care planning improves care and outcomes in prostate cancer survivors receiving radiation therapy and androgen deprivation therapy.
- Trial name
- NCT03860961
- Testing
- Survivorship Care Plan, Treatment Plan
- Where
- 79 sites in United States
- Volunteers
- 550 people
- Sponsor
- NRG Oncology
Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma
A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer
This phase II trial studies the side effects of radiation therapy [hypofractionated proton beam radiation therapy (PBRT) or intensity-modulated radiation therapy (IMRT)] for the treatment of prostate cancer that has come back…
- Conditions
- Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
- Trial name
- NCT04190446
- Testing
- Intensity-Modulated Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Mayo Clinic
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
This phase II trial studies how well hypofractionated radiation therapy works in treating participants with prostate cancer high-risk features following radical prostatectomy.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
- Trial name
- NCT03570827
- Testing
- Androgen Suppression, Hypofractionated Radiation Therapy, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Mayo Clinic